Hackensack Meridian Health
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Hackensack Meridian Health sits in the top decile of US sponsors by registered trial count (#261 of 15,742 sponsors by registered trial count).
Hackensack Meridian Health: 90 sponsored US clinical trials, 23 recruiting.
Hackensack Meridian Health sponsors 90 registered US clinical trials on ClinicalTrials.gov, 23 of them currently recruiting, and 34 completed. 6 of these trials are in Phase 3-4 (later-stage) and 43 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Myeloma, with 5 trials.
Top-decile sponsor footprint
Hackensack Meridian Health ranks in the top decile of sponsors by registered trial count (#261 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
34 of 62 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (54.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
90 total, page 2 of 2
Personal Resilience Empowerment Program Study
NCT03644173
A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT03136497
Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer
NCT03586297
The Effectiveness of Osteopathic Manipulative Medicine in the Management of Headaches Associated With Post Concussion Syndrome
NCT04732338
NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
NCT03232424
A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes
NCT02624804
Effectiveness of Using Educational Modules Via Bedside Tablet in Newly Diagnosed Type 1 Diabetes
NCT03534193
Central Venous Access Study
NCT03480542
HUMC 1612: Optune NovoTTF-200A System
NCT03128047
AroMatherapy for Blood and Marrow Transplant PatIENTs (AMBIENT)
NCT03621722
Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
NCT02906332
Accurate Display of Postpartum Hemorrhage Using Triton (ADOPT)
NCT02981758
Trial of Exercise to Reduce Cancer Related Fatigue in Breast Cancer
NCT02846389
Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence
NCT02681302
Start Time Optimization of Biologics in Polyarticular JIA
NCT02593006
Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation
NCT02338232
The IMPROVE Study-IMPact of a Regulated ADC System
NCT02228694
A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531
NCT01813227
Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide
NCT01723839
Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens
NCT01502085
In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus
NCT01453140
Stem Cell Transplantation for Sickle Cell Anemia
NCT01877837
Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL
NCT01241734
Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL
NCT01241786
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
NCT01453088
Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation
NCT01366612
Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
NCT01453101
Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT
NCT01242267
Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
NCT01241708
Pediatric Head Lice Study Product Comparison
NCT02213055
PRO#0118: Decitabine Plus Mini Flu-Bu
NCT01455506
Correlation Between CPAP Compliance and Food Intake Timing
NCT01851811
PET-CT Scans in Healthy Volunteers After Flu Vaccination
NCT00769002
The Biology of Claudin 3 in Primary Human Mammary Epithelial Cell Culture
NCT00481585
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
NCT00464178
Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma
NCT00784823
Lived Experiences of Adolescents in the Treatment Process of Cancer and the Impact on Occupations
NCT00456209
To Study the Prevalence of Insomnia in Geriatric COPD Patients Who Are Enrolled in a Pulmonary Rehabilitation Program.
NCT00346554
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer
NCT00004906
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer
NCT00004900
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 24 |
| Phase 2 | 19 |
| Phase 3 | 4 |
| Phase 4 | 2 |
What is open in the Hackensack Meridian Health pipeline
23 recruiting of 90 indexed (26% open); 34 completed (38%).
Phase mix: 6 late (III/IV) vs 43 early (I/II) (early-phase heavy).
Top condition: Multiple Myeloma (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Hackensack Meridian Health: open-pipeline peers nationwide
Peers matched on 90 registered trials and 26% open enrollment, not the therapeutic-area sidebar.
Hackensack Meridian Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 90 trials (± recruiting share)
- ModernaTX · 90 trials · 14% recruiting
- National Institute of Dental and Craniofacial Research (NIDCR) · 91 trials · 12% recruiting
- University of Central Florida · 91 trials · 42% recruiting
- Abbott Nutrition · 89 trials · 1% recruiting
Sponsors near 26% open enrollment (± trial volume)
- Syracuse University · 26% recruiting · 31 trials
- Shirley Ryan AbilityLab · 26% recruiting · 138 trials
- University Health Network, Toronto · 26% recruiting · 23 trials
- AB Science · 25% recruiting · 8 trials
Related
What to do with this Hackensack Meridian Health page
90 registered trials is a research-attention snapshot, not an endorsement of Hackensack Meridian Health or any single study.
- 23 of Hackensack Meridian Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Myeloma is the condition Hackensack Meridian Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Myeloma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Hackensack Meridian Health pipeline card: 90 registered trials from official public datasets.Report a data error.